Kancera AB (publ) presents new information on - how the company's Fractalkine blocker prevents immune cells (monocytes) to infiltrate the nerves and spinal cord, which prevents nerve damage and enhanced pain sensitivity associated with cancer treatment - the fact...
Read MoreThis is a translation from a swedish press release Stockholm dated 2016-12-23. Kancera AB (publ) today announced that Joachim Forsgren (MD, PhD) has been appointed Chief Medical Officer and will be medically responsible for Kancera product portfolio. He will...
Read MoreKancera AB (publ) today reported that the drug candidate KAN0440567 quickly and effectively counteracts the kind of pain that results from chemotherapy and that often prevents effective treatment of cancer. The results also indicate that the Kancera drug candidate...
Read MoreIn connection with a presentation at the Swedish Shareholders' Association on 17 November in Vimmerby, Kancera communicates new results in the ROR project. These results indicate that the company's ROR inhibitors may work against a particular type of intractable...
Read MoreKancera AB (publ) announced today that Niclas Brynne has been appointed to lead Kancera's clinical development projects. He will be part of the management team and report directly to the CEO.
Read MoreKancera reports that the Fractalkine antagonist KAN0440567 is able to eliminate pain resulting from inflammation of the pancreas and that the ROR inhibitor KAN0439834 has been shown to effectively kill resistant cancer cells from the bone marrow of multiple...
Read MoreDue to positive efficacy data in disease models of cancer and pain, Kancera's Board of Directors has decided to exercise the exclusive option to acquire the Fractalkine project.
Read MoreKancera reports that ROR inhibitors have been tested against human triple negative breast cancer transferred to zebrafish. The experiments showed that Kancera's small molecule ROR inhibitors are able to both reduce tumor size and metastases (spread) of this aggressive...
Read MoreKancera reported that the company has developed a new series of ROR inhibitors that show improved pharmaceutical properties which will allow preclinical studies of their effect on e.g. solid tumors. These results have prompted Kancera to concentrate the investments...
Read MoreKancera's patent covering small molecule inhibitors of PFKFB3 has been approved in the United States. Further, a patent application covering new chemical series in the HDAC6 project has been filed according to plan. In the ROR project, the company...
Read More